

(III) TO THE EXTENT CONSISTENT WITH FEDERAL AND STATE LAW, REFLECTS THE INTELLECTUAL PROPERTY POLICIES OF THE INSTITUTION.

(D) A MEMORANDUM OF UNDERSTANDING ESTABLISHED UNDER SUBSECTION (C)(2) OF THIS SECTION MAY ALLOW FOR THE SELECTION OF A HIGHER EDUCATION INSTITUTION OR PRIVATE ENTITY TO EXPEDITE THE TRANSLATION OF CANCER RESEARCH ACTIVITIES INTO TREATMENT PROTOCOLS AND CLINICAL TRIALS.

(E) THE DEPARTMENT MAY NOT DISTRIBUTE A TOBACCO-RELATED DISEASES RESEARCH GRANT UNLESS THE DEPARTMENT FIRST DETERMINES THAT:

(1) THE TOBACCO-RELATED DISEASES RESEARCH PLAN WILL HELP ACHIEVE THE STATE'S PUBLIC HEALTH GOALS;

(2) THE UNIVERSITY OF MARYLAND MEDICAL GROUP WILL NOT USE ANY PART OF THE GRANT TO SUPPLANT THE FUNDING FOR ANY EXISTING EDUCATION, SCREENING, TREATMENT, AND RESEARCH ACTIVITIES RELATING TO TOBACCO-RELATED DISEASES OR ANY OTHER TYPE OF CURRENT EXPENDITURE BY THE INSTITUTION;

(3) THE GRANT WILL BE USED TO CONDUCT RESEARCH IN THE AREAS SPECIFIED IN SUBSECTION (B) OF THIS SECTION;

(4) THE INSTITUTION HAS EXECUTED A MEMORANDUM OF UNDERSTANDING AS REQUIRED BY SUBSECTION (C)(2) OF THIS SECTION; AND

(5) THE INSTITUTION SATISFIES ANY OTHER REQUIREMENT ESTABLISHED BY THE DEPARTMENT AS A CONDITION OF RECEIVING THE GRANT.

(F) EACH YEAR, THE DEPARTMENT SHALL EVALUATE THE EFFICIENCY AND EFFECTIVENESS OF THE RESEARCH THAT IS CONDUCTED UNDER A TOBACCO-RELATED DISEASES RESEARCH GRANT.

13-1117 13-1118.

(A) THE DEPARTMENT MAY DISTRIBUTE A ~~MEDICAL INSTITUTION STATEWIDE ACADEMIC HEALTH CENTER NETWORK~~ GRANT TO THE UNIVERSITY OF MARYLAND ~~MEDICAL SYSTEM GROUP, AS ALLOCATED IN THE STATE BUDGET,~~ FOR THE PURPOSE OF ESTABLISHING A STATEWIDE NETWORK ~~AND INFRASTRUCTURE~~ THAT WILL SUPPORT A WIDE RANGE OF PREVENTION, EDUCATION, OUTREACH, SCREENING, TREATMENT, AND RESEARCH PROGRAMS RELATING TO TARGETED CANCERS AND TOBACCO-RELATED DISEASES THAT CAN BE ACCESSED BY INDIVIDUALS THROUGHOUT THE STATE, INCLUDING:

(1) ~~REGIONAL COORDINATION OF CLINICAL TRIALS SUPPORT SERVICES~~ AIMED AT INCREASING PARTICIPATION OF DIVERSE POPULATIONS IN CLINICAL TRIALS;

(2) DEVELOPMENT OF BEST PRACTICES MODELS ~~FOR~~ TO ADDRESS TARGETED CANCERS AND TOBACCO-RELATED DISEASES; AND